ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
We assessed the pharmacokinetics and interaction of ABT-773 in 12 volunteers receiving ABT-773 alone or concomitantly with ranitidine or sucralfate. Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng. h/ml. Coadministration of ranitidine, reduced the C(max) (-25.7%) and AUC(0- infinity ) (-15.8%) significantly. Sucralfate had no impact on the bioavailability of ABT-773.
Pletz
M W
MW
Department of Chest and Infectious Diseases, E. von Behring City Hospital, Free University of Berlin, Germany.
Preechachatchaval
V
V
Bulitta
J
J
Allewelt
M
M
Burkhardt
O
O
Lode
H
H
D000328:Adult; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000494:pharmacology*; D019540:Area Under Curve; D001681:Biological Assay; D002853:Chromatography, Liquid; D018592:Cross-Over Studies; D004347:Drug Interactions; D004917:Erythromycin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000494:pharmacology*; D005260:Female; D006801:Humans; D048628:Ketolides; D008297:Male; D013058:Mass Spectrometry; D008826:Microbial Sensitivity Tests; D011899:Ranitidine / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000494:pharmacology*; D013392:Sucralfate / Q000009:adverse effects / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D048628:Ketolides; D013392:Sucralfate; D004917:Erythromycin; D011899:Ranitidine; C405499:cethromycin